Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00832520 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00832520 is a Phase 2 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 13 participants.
The verdict
NCT00832520, a Phase 2 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if remeron, also called mirtazapine, can help you prevent weight loss while on treatment for your cancer. Remeron is currently used to treat depression and has not been approved by the Food and Drug Administration for use to treat weight loss.
Interventions
- DRUG Remeron (mirtazapine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00832520
The ClinicalTrials.gov registry entry for NCT00832520 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Remeron (mirtazapine) is the first listed.
NCT00832520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00832520 about?
NCT00832520 is a clinical study titled "Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight". The purpose of this study is to find out if remeron, also called mirtazapine, can help you prevent weight loss while on treatment for your cancer. Remeron is currently used to treat depression and has not been approved by the Food and Drug Administration for use to treat weight loss.
What is the current status of trial NCT00832520?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2008-11. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00832520?
The interventions under investigation include: Remeron (mirtazapine) (DRUG).
Who is sponsoring clinical trial NCT00832520?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.